This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
KIF20B · Western blot design guide
KIF20B Western Blot Planning Guide
Plan a KIF20B Western blot around the catalog-observed 210.6 kDa band, image-backed A08340 evidence, HPA controls, and verified protocol records.
Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
KIF20B Western Blot Experimental Design Guide
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | 210.6 kDa | |
| Observed band | Not reported — verify product WB image | |
| Gel | 4-12% gradient | |
| Positive control | Bone marrow | |
| Negative control | Duodenum |
Important caveats
Reasons your observed band may differ from the expected size.
| ⓘ | Calculated mass | 210.6 kDa |
| ⓘ | Localization | Nucleus / Cytoplasm, cytoskeleton, microtubule organizing center, centrosome |
| ⓘ | Processing / PTM | Record-dependent |
| ⓘ | Reactivity | Human / Mouse / Rat |
Sample controls for KIF20B Western blot
🧪Use Bone marrow as the first positive-control candidate and Duodenum as the HPA Not detected negative candidate.
Positive control: Bone marrow (High)
Negative control: Duodenum (Not detected)
HPA protein score determines control status; other expression data is supporting context only.
HPA tissue expression evidence for KIF20B
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart on each tissue page — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Bone marrow | Reported tissue cells | High | Protein (HPA) | HPA → |
| Gallbladder | Reported tissue cells | Medium | Protein (HPA) | HPA → |
| Adrenal gland | Reported tissue cells | Medium | Protein (HPA) | HPA → |
| Pancreas | Reported tissue cells | Medium | Protein (HPA) | HPA → |
Section 1
What Is the Expected KIF20B Western Blot Band Size?
Use the product-observed 210.6 kDa band as the primary planning value and retain the UniProt calculated mass as context.
| 210.6 kDa | Matches the authoritative product WB observation. |
| 210.6 kDa calculated | Use as UniProt context, not as a replacement observed band. |
| Unexpected additional signal | Do not assign identity without orthogonal positive/negative controls. |
💡Expected KIF20B appearancePlan around 210.6 kDa and keep the calculated mass as supporting context.
| Catalog-observed band | 210.6 kDa; use this as the primary experimental expectation. |
| Calculated mass | 210.6 kDa from UniProt Q96Q89; retain as context. |
| Gel selection | 4-12% gradient; shared with the recommended protocol and poster. |
| Specificity check | Compare the lead HPA positive and negative controls with A08340. |
| Situation | Likely cause | Next action |
|---|---|---|
| 210.6 kDa | Matches the authoritative product WB observation. | Confirm with orthogonal controls and the linked product record. |
| Additional band | May reflect processing, modification, or non-specific signal. | Run a dilution series and compare positive/negative controls. |
| Weak signal | Target abundance or transfer may be limiting. | Verify transfer, increase positive-control abundance, and bracket exposure. |
Experiment evidence
Western blot images showing KIF20B band
A08340 · KIF20BObserved 210.6 kDa · product-specific WB image
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Section 2
Real Curated KIF20B Western Blot Protocols
Start with the molecular-weight rule, then compare verified publication-derived conditions.
| Sample / lysate | Bone marrow |
| Gel % | 4-12% gradient |
| Load | 20-30 µg total protein per lane |
| Transfer | Wet/tank, extended transfer |
| Membrane | 0.45 µm PVDF |
| Blocking | 5% non-fat milk or 5% BSA in TBST |
| Primary | A08340 at datasheet starting dilution |
| Primary incubation | Overnight at 4 °C with gentle agitation |
| Secondary | Species-matched HRP conjugate at validated dilution |
| Wash | 3 × 5 min in TBST |
| Detection | Chemiluminescent substrate |
| Exposure | Bracket exposures to avoid saturation |
Section 4
Advanced KIF20B Western Blot Tips
Deeper troubleshooting and optimisation questions for KIF20B, answered from its protein features.
Which band should guide the blot?
Use 210.6 kDa, the observation attached to the authoritative A08340 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 210.6 kDa expectation.
Which positive control should I start with?
Start with Bone marrow, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Duodenum as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 4-12% gradient consistently across the quick facts, protocol table, and poster.
What transfer method to use for KIF20B Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should A08340 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
Compare only the supplied target-verified records: PMC6709729, PMC8445734, PMC11995485.
Boster reagents
KIF20B Western Blot Reagents
Human/Mouse/Rat-reactive KIF20B Western blot reagents with authoritative product imagery.
Real WB data
Anti-MPP1/KIF20B Antibody Picoband®
Cat # A08340
Reactivity: Human, Mouse, Rat
Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.
Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.
References
- UniProt Q96Q89
- Human Protein Atlas — KIF20B
- A08340 product record
- PMC6709729 — A Monoclonal Antibody to M-Phase Phosphoprotein 1/Kinesin-Like Protein KIF20B.
- PMC8445734 — KIF20B Promotes Cell Proliferation and May Be a Potential Therapeutic Target in Pancreatic Cancer.
- PMC11995485 — Inhibition of miR-325 inhibits KIF20B expression and the colorectal cancer cells' invasion & proliferation.